Oregon introduces pricing transparency bill

Home/Policies & Legislation | Posted 27/04/2018 post-comment0 Post your comment

The US State of Oregon has signed a new bill into law that requires drugmakers to provide data justifying price hikes.

Capsules visual V16A24DG

House Bill 4005 was signed into law on 12 March 2018 by Oregon Governor Kate Brown. The Oregon Senate passed the bill on 2 March 2018 with a vote of 25−4. This was preceded by a vote of 46−14 on the same bill in the House in February.

HB 4005 requires drug companies to file annual reports with the state outlining price increases of drugs that cost at least US$100 per month and why prices were hiked. They are also required to report profits, as well as manufacturing, R & D and marketing costs, and identify generics for any drug where the price has increased by more than 10% compared to the previous year. Other data required includes information on the 10 highest prices paid for the prescription drug during the previous calendar year in any country other than the US and on the total value of the coupons, discounts, co-payment assistance or other reduction in costs provided to consumers.

Oregon’s Department of Consumer and Business Services is also required to publish a list of drugs with high price increases.

The first reports are due by 1 July 2019. Manufacturers that fail to comply could face fines of up to US$10,000 per day of violation, based on the severity of each violation.

Oregan is not the only state trying to address the increasing price of prescription drugs in the US. Nevada and California advanced measures requiring manufacturers to disclose operating costs and give early notification of any planned price increases. Maryland’s governor, Larry Hogan, meanwhile allowed a law targeting generic drug ‘price gouging’ to become law without his signature [1].

Related article
Policies to address price rises in old generics

1. GaBI Online - Generics and Biosimilars Initiative. US states progress drug-pricing legislation [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Apr 27]. Available from: www.gabionline.net/Policies-Legislation/US-states-progress-drug-pricing-legislation

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.

Source: LegiScan

comment icon Comments (0)
Post your comment
Related content
Nomenclature of biologicals and biosimilars in Peru
02 AA010638
Home/Policies & Legislation Posted 20/05/2022
United States legislation to improve access to insulin
Insulin 1 V13C03
Home/Policies & Legislation Posted 29/04/2022
Nomenclature of biologicals and biosimilars in Chile
Home/Policies & Legislation Posted 22/04/2022
Nomenclature of biologicals and biosimilars in Colombia
Colombia V14I19
Home/Policies & Legislation Posted 08/04/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010